For the quarter ending 2025-09-30, INTI has $3,135,167 in assets. $3,131,714 in debts. $2,976,658 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 2,976,658 | 3,737,903 | ||
| Prepaid expenses and other assets | 87,428 | 92,025 | ||
| Total current assets | 3,064,086 | 3,829,928 | ||
| Operating lease right-of-use assets | 71,081 | 77,734 | ||
| Total assets | 3,135,167 | 3,907,662 | ||
| Accounts payable | 19,646 | 106,249 | ||
| Accrued expenses and other liabilities | 40,432 | 7,725 | ||
| Current portion of operating lease obligations | 27,455 | 25,987 | ||
| Total current liabilities | 87,533 | 139,961 | ||
| Deferred revenue | 3,000,000 | 3,000,000 | ||
| Operating lease obligations, less current portion | 44,181 | 52,064 | ||
| Total liabilities | 3,131,714 | 3,192,025 | ||
| Preferred stock, value-Series APreferred Stock | 0 | 0 | ||
| Preferred stock, value-Series BConvertible Preferred Stock | 0 | 0 | ||
| Preferred stock, value-Undesignated Preferred Stock | 0 | 0 | ||
| Common stock, 0.0001 par value 500,000,000 shares authorized 172,573,545 and 172,323,545 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 17,257 | 17,257 | ||
| Additional paid-in capital | 54,110,425 | 54,110,425 | ||
| Accumulated deficit | -54,124,229 | -53,412,045 | ||
| Total stockholders equity | 3,453 | 715,637 | ||
| Total liabilities and stockholders equity | 3,135,167 | 3,907,662 | ||
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)